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Effects of DNA and protein size on substrate cleavage by human
tyrosyl-DNA phosphodiesterase 1 (TDP1)
Heidrun Interthal*,1 and James J. Champoux*,2
*Department of Microbiology, School of Medicine, Box 357242 University of Washington, Seattle,
Washington, 98195 USA
Abstract
Tyrosyl-DNA phosphodiesterase 1 (TDP1) catalyzes the hydrolysis of phosphodiester linkages
between a DNA 3′ phosphate and a tyrosine residue as well as a variety of other DNA 3′
substituents, and has been implicated in the repair of covalent complexes involving eukaryotic
type IB topoisomerases. To better understand the substrate features that are recognized by TDP1,
the size of either the DNA or protein component of the substrate was varied. Competition
experiments and gel shift analyses comparing a series of substrates with DNA lengths increasing
from 6 to 28 nucleotides indicated that, contrary to predictions based on the crystal structure of the
protein, the apparent affinity for the substrate increased as the DNA length was increased over the
entire range tested. It has previously been found that a substrate containing the full-length native
form of human topoisomerase I protein is not cleaved by TDP1. Protein-oligonucleotide
complexes containing either a 53 or 108 amino acid long topoisomerase I-derived peptide were
efficiently cleaved by TDP1, but like the full length protein, a substrate containing a 333 amino
acid topoisomerase I fragment was resistant to cleavage. Consistent with these results, evidence is
presented that processing by the proteasome is required for TDP1 cleavage in vivo.
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Introduction
Cleavage of the DNA backbone by a topoisomerase is accompanied by the formation of a
covalent bond between a tyrosine side chain in the enzyme and the phosphate at the site of
cleavage [1]. The type I topoisomerases cleave one of the two DNA strands to form a
covalent intermediate that involves a 5′-phosphate for the members of the type IA subfamily
and a 3′-phosphate for the members of the type IB subfamily. Human topoisomerase I
belongs to the type IB subfamily and provides temporary single-strand breaks to enable the
removal of torsional stress associated with DNA replication, transcription, recombination,
and likely chromatin remodeling [1-4].
Although topoisomerase I cleavage is normally followed by religation of the DNA, the
presence of nicks, strand gaps, mismatched bases, or modified nucleotides in the DNA near
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where the topoisomerase cleaves can cause a failure in religation and trap the topoisomerase
on the DNA [5]. In addition, members of the camptothecin family of anticancer drugs
specifically intercalate into the DNA at the site of topoisomerase I cleavage and block
religation [6-9]. Genetic studies in yeast indicate that multiple pathways exist for the repair
of this type of topoisomerase I-mediated DNA damage [10-13]. These studies have
implicated tyrosyl-DNA phosphodiesterase (TDP1) [14] and the structure-specific
endonucleases Rad1/Rad10 and Mus81/Mms4 in these repair processes. TDP1 is also
implicated in the repair of stalled topoisomerase I complexes in human cells [15-18]. The
strong preference of TDP1 for removing a tyrosine residue from the ends of single- or
double-stranded DNA substrates in vitro as opposed to a tyrosine located at a nick on duplex
DNA [13, 14, 19, 20] suggests an involvement of the enzyme in the removal of adducts from
ends rather than internal sites on DNA. However, TDP1 has also been implicated in the
repair of single-strand breaks caused by abortive topoisomerase I-DNA complexes [16] and
by ionizing radiation [21].
TDP1 was discovered by virtue of its ability to hydrolyze a tyrosyl O-4 ester linkage to a
DNA 3′ phosphate [14], but more recently has been shown to also catalyze the hydrolytic
removal of a variety of other moieties from the 3′ end of DNA. One such adduct is a 3′-
phosphoglycolate substituent which is consistent with a role for TDP1 in the repair of
damage caused by ionizing radiation [10, 22, 23]. In addition, we previously showed that 3′
ends with a free hydroxyl (a nucleoside), an abasic residue, or an artificial biotin adduct are
substrates for TDP1 [24]. It has also been reported that yeast TDP1 is capable of
hydrolyzing DNA 5′ phosphotyrosyl linkages [25], suggesting a possible role for the yeast
enzyme in the repair of topoisomerase II covalent complexes, although such a 5′ processing
activity has not been found for human TDP1 [14, 20]. Notably, a human enzyme with a 5′
cleavage activity has recently been reported and referred to as TDP2 (TTRAP) [26].
As with other members of the phospholipase D superfamily [27-29], the reaction catalyzed
by TDP1 proceeds through a covalent intermediate in which an active site histidine (His263
in human TDP1) is linked by a phosphoamide bond to the DNA 3′ phosphate from the
substrate [29, 30]. As an example of the versatility of the enzyme, TDP1 can also hydrolyze
this DNA 3′ phosphoamide linkage [24, 29, 31, 32], a reaction that likely explains the
recessive nature of the neurodegenerative disorder spinocerebellar ataxia with axonal
neuropathy (SCAN1) [33] in which a H493R mutation in the TDP1 gene causes the
accumulation of the TDP1-DNA covalent intermediate in vivo [17, 18].
By exploiting our observation that vanadate will promote the assembly of a quaternary
complex involving TDP1, a short DNA oligonucleotide, and a peptide, we previously used
X-ray crystallography to characterize the transition state for the reaction that forms the
enzyme-DNA covalent intermediate [31, 34]. These data provide key insights into the
mechanism of the reaction and how the protein and DNA moieties of the substrate interact
with the enzyme in the immediate vicinity of the active center. Notably, a groove exists that
emanates from the active center and appears capable of binding a single strand of DNA
approximately 6 nucleotides in length. Paradoxically, this groove is too narrow to
accommodate a double-stranded region of DNA. In opposition to this groove is a relatively
large concave pocket that accommodates the peptide moiety of the substrate. Attempts to
structurally model an intact version of human topoisomerase I into this pocket and maintain
the correct configuration for TDP1 cleavage were unsuccessful [31]. This finding would
explain the inability of TDP1 to remove an intact topoisomerase I from the 3′ end of DNA
[24, 35] and is consistent with an earlier suggestion that the topoisomerase I must be
modified in vivo, most likely by unfolding or proteolysis, before TDP1 cleavage [14].
Interthal and Champoux Page 2
Biochem J. Author manuscript; available in PMC 2011 August 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Here we vary the size of both the DNA and the protein portions of the substrate to elucidate
how the substrate interacts with the enzyme at regions more distal from the active center.
Specifically, we investigated the effects of varying the DNA length from 6 to 28 nucleotides
for a substrate containing a 7 amino acid long topoisomerase I-derived peptide. We also
varied the size of the protein moiety of the substrate to gain further insights into the extent of
proteolysis required prior to TDP1 cleavage. Finally, we show that the activity of the
proteasome is required in vivo for TDP1 cleavage of topoisomerase I-DNA covalent
complexes.
Materials and Methods
Proteins and reagents
The procedures for the purification of topo70, an N-terminal truncated form of human
topoisomerase I missing the first 174 amino acids, topo31, and human TDP1 have been
previously published [29, 36]. The generation of the following reconstituted forms of
topoisomerase I has been described previously: topo56/6.3, topo58/12, and topo31/topo39
[37, 38]. Antibodies against human TDP1 were generated as described [17]. Human
scleroderma serum (Scl-70 from Immunovision, Springdale, Arizona) was used in the ICE
immunoblot experiments to detect topoisomerase I. Affinity purified rabbit antibodies
against human topoisomerase I were used for the whole cell extract immunoblots. Anti-actin
antibodies were purchased from Sigma.
Preparation of TDP1 substrates
The preparation of the 12-mer oligonucleotide with a 3′ trypsin-resistant peptide derived
from human topoisomerase I (12-pep) has been described previously [29]. Briefly, topo70
was incubated with a partially duplex suicide substrate (CL14N:CP25N) containing a strong
topoisomerase I cleavage site two nucleotides from the 3′ end of the scissile strand (CL14N:
5′ GAAAAAAGAGTTAG 3′). After allowing sufficient time for essentially all of the
substrate to become covalently linked to the enzyme, the products were treated with trypsin
and the shortened scissile strand was gel-purified and 5′ end-labeled with polynucleotide
kinase (New England Biolabs) and [γ-32P]ATP (NEN Life Sciences Products) prior to use as
a substrate for TDP1. The other peptide substrates (6-pep, 19-pep and 28-pep) were
similarly prepared using suicide substrates with the appropriate length scissile strands (CL8:
5′AGAGTTAG 3′; CL21: TAGAGGATCTAAAAGACTTAG 3′; CL30:
GGTCGACTCTAGAGGATCTAAAAGACTTAG 3′).
A series of topoisomerase I-derived protein fragments containing a covalently attached 12-
mer oligonucleotide were prepared as follows. Topo70 and the reconstituted forms of the
enzyme (topo56/6.3, topo58/12, and topo31/39) were incubated with the CL14:CP25N
suicide substrate and the respective covalent complexes containing the 12-mer
oligonucleotide (12-topo70, 12-topo6.3, 12-topo12, and 12-topo39) were purified by SDS-
PAGE (15% gel). The proteins were denatured with guanidine hydrochloride and renatured
as described by Hager and Burgess [39]. The suicide substrate contains a second weak
cleavage site four nucleotides from the 3′ end of the scissile strand that generates a small
amount of 10-topo70, 10-topo6.3, 10-topo12, and 10-topo39. After trypsin treatment, these
substrates are converted to 10-pep which along with the corresponding TDP1 product, 10-P,
are visible in the sequencing gels used for the analysis of the TDP1 reactions.
Competition TDP1 cleavage reactions
Pairs of labeled peptide substrates (19pep/12-pep, 12-pep/6-pep, 19-pep/6-pep, and 28-pep/
19-pep) at a final concentration of 2 nM each were incubated with TDP1 at room
temperature (22 °C) for the indicated times in Assay Buffer (10 mM Tris-HCl (pH 7.5), 100
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mM KCl, 1 mM EDTA, 1 mM DTT). The enzyme concentration was 23 nM except for the
19-pep/12-pep pair where the enzyme concentration was 4.6 nM. Samples were removed at
various time intervals and the reactions quenched by addition of an equal volume of
formamide loading buffer as described previously [29]. The products were analyzed by
electrophoresis in a 15% sequencing gel, the dried gels were scanned using a
PhosphorImager, and the band intensities determined using ImageQuant software
(Amersham Biosciences). For purposes of quantitation, the substrates and products resulting
from cleavage at the both the primary cleavage site and the weaker secondary cleavage site
were summed.
Gel shift experiments
To prevent cleavage of the peptide substrates during the course of the experiment, the
catalytically inactive H263A mutant form of TDP1 [29] was used for the gel shift analyses.
The four labeled peptide substrates (6-pep, 12-pep, 19-pep, and 28-pep) (0.15 nM) were
incubated at 4°C in Assay Buffer containing 12.5% glycerol (final volume 20 μl) with two-
fold increasing concentrations of TDP1 (from 23 nM up to 1.46 μM) and the samples (16 μl
portions) were analyzed by electrophoresis in a nondenaturing 5% gel at 4°C as described
[40, 41]. The gels were dried, scanned using a PhosphorImager and band intensities
determined using ImageQuant software as described above. For the 19-pep and the 28-pep
substrates, Kd values were estimated from the concentration of substrates at which half of
the substrate was shifted in mobility [42].
TDP1 cleavage of the protein-oligonucleotide substrates
For the cleavage assays, the protein-oligonucleotide covalent complexes (12-topo70, 12-
topo39, 12-topo12, and 12-topo6.3) were incubated with TDP1 in Assay Buffer at room
temperature for 20 min. The reactions were stopped by the addition of SDS (0.6%), followed
by precipitation with ethanol and treatment with trypsin [17] to convert all of residual
substrate to 12-pep and a small amount of 10-pep before analysis in a 15% sequencing gel.
The religation controls were performed as follows. The religation oligonucleotide pair
consisted of CP25N (the nonscissile strand of the suicide substrate) which was
complementary at its 3′ end to the 12-mer attached to the proteins and a 13-mer acceptor
oligonucleotide (REL13) which was annealed to the 5′ half of CP25N. Religation by the 12-
topo70 covalent complex was initiated by the addition of the religation oligonucleotide pair.
To enable the covalently bound protein fragments to carry out religation, topo31 was added
to 12-topo39, and topo58 was added to 12-topo12 and 12-topo6.3. Religation generated a
labeled 25-mer oligonucleotide product that was visualized on the sequencing gel used for
the assays. To simplify the analyses, the samples were treated with trypsin as described
above to reduce all of the protein-oligonucleotide complexes to 12-pep (and the minor 10-
pep species) prior to analysis on a 15% sequencing gel.
Cell culture and ICE assays
SCAN1 fibroblasts were treated for 1 h with 20 μM CPT (Sigma) and the cells lysed
immediately with 0.8 % SDS and analyzed by a modified ICE assay [18, 43]. Where
indicated, the cells were pretreated for 1 h with 20 μM MG132 or for 2h with 40 μM
lactacystin prior to, and during the CPT treatment. DNA in the extract was lightly sheared
by passage through a syringe and the samples diluted approximately 8-fold with 1% N-
lauroyl-sarcosine before being loaded onto a 1.5 g/cc CsCl cushion. After centrifugation at
20°C for 20 h at 165,000 × g (Beckman SW41 Ti rotor), the pellet fraction containing the
bulk of the high molecular DNA plus any covalently bound proteins was treated with 300
units of micrococcal nuclease in 20 mM Tris-HCl (pH 8.0), 10 mM NaCl, 2mM CaCl2 in a
final volume of 50 μl. The samples were subjected to an immunoblot analysis in which the
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membrane was first probed for TDP1 and then topoisomerase I as described [17]. The whole
cell extracts were similarly analyzed on immunoblots with probing for TDP1, topoisomerase
I, and β-actin.
Results
Effect of DNA length on TDP1 cleavage
To compare the effect of DNA length on substrate preference for TDP1, we chose to utilize
a form of the substrate where the protein moiety was a short 7 amino acid long trypsin-
resistant peptide derived from human topoisomerase I [24, 29]. This choice ensured that the
protein moiety would be small enough to be compatible with efficient and unhindered
cleavage while at the same time preserving the immediate amino acid context of a known
natural substrate of the enzyme. To generate the substrate, human topoisomerase I was
incubated with a DNA oligonucleotide suicide substrate until cleavage was complete,
followed by treatment with trypsin and gel purification (see Material and Methods). Since
the Km of human TDP1 is in the micromolar range [44, 45] and we could only prepare
sufficient quantities of these substrates to achieve nanomolar concentrations, we were
unable to employ standard Michaelis-Menten substrate saturation experiments to directly
measure the kinetic parameters for the reaction as a function of DNA length. However, the
ratio of the reaction velocities for two competing substrates A and B (vA/vB) when present at
the same concentration in a reaction is equal to the ratio of the specificity constants (kcat/Km)
for the substrates as shown by the relationship below [46]. Importantly, this equation holds
for all substrate concentrations.
Since this type of analysis does not yield true values for kcat/Km, the objective of these
experiments was to compare the rates of cleavage for two competing substrates in a reaction
as an indicator of the relative specificity constants for the substrates. In this way, we could
order the substrates with different DNA lengths according to their relative efficiencies of
cleavage. Initially, three DNA-peptide substrates were prepared containing 5′ 32P end-
labeled single-stranded oligonucleotides with lengths of 6, 12 and 19 (referred to as 6-pep,
12-pep and 19-pep, respectively) and competed in pair wise combinations for cleavage by
human TDP1. For all three substrate pairs tested, the substrates and the corresponding TDP1
products containing 3′ phosphates had distinct mobilities in a sequencing gel, enabling us to
follow both the disappearance of the substrates and the kinetics of appearance of the
products in the competition reactions (Figure 1). As can be seen in the sequencing gel
analyses shown in Figure 1(A), the rate of cleavage of 12-pep exceeded that of 6-pep while
19-pep in turn was cleaved faster than 12-pep and not surprisingly, 19-pep was cleaved
much faster than 6-pep. These results were quantified by PhosphorImager analysis of three
independent experiments for each pair and the rate of disappearance for the 19-pep/12-pep
and 12-pep/6-pep pairs is shown graphically in Figs. 1B and 1C. To extend these results to a
substrate with yet a longer DNA, we similarly compared 28-pep with 19-pep as substrates
and again the longer substrate was cleaved faster (Figure 2).
These results were surprising in view of the crystal structure of TDP1 showing that the most
likely binding trajectory for single-stranded DNA follows a narrow groove on the surface of
the enzyme that can accommodate at most six nucleotides [31]. However, as described
above, these relative reaction rates reflect the specificity constants for the different
substrates (kcat/Km) and even if the kcat values for the different substrates were similar, Km is
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only equal to the dissociation constant for the enzyme-substrate complex under limiting
conditions where the rate of dissociation of the complex is fast relative to kcat. Thus, it was
of interest to use an independent method to compare directly the relative binding affinities of
the enzyme for the different substrates. Figure 3 shows a series of gel-shift experiments for
the same four substrates employed in the substrate competition analyses. To prevent
cleavage of the substrates during the course of the assays, the catalytically inactive H263A
mutant form of human TDP1 was used in these gel shift binding experiments [29]. Although
a discrete shifted species could only be seen for the 19-pep and 28-pep substrates (Figure 3C
and D), it appears that the affinity of the enzyme for the DNA-peptide complexes does
indeed increase as the length of the DNA increases from 6 to 28. For the longer substrates,
the substrate concentration at which half of the substrate was shifted to a slower mobility
[42] yielded approximate Kd values of 130 nM and 40 nM, respectively, confirming the
impression from the raw data that TDP1 does indeed have a higher affinity for 28-pep than
for 19-pep. The value of 130 nM for the 19-pep compares very well with a previously-
published value of 150 nM for a similar single-stranded substrate with a length of 16
nucleotides [19]. The apparent super-shifted species for 28-pep at the four highest substrate
concentrations (Figure 3D) was possibly due to the binding of two molecules of TDP1 to
this longer substrate. These results strongly suggest that the contribution of increasing DNA
length to the binding affinity has a significant effect on the reaction rates observed in the
substrate competition experiments. Thus, it appears that the proposed interaction of the
DNA with the previously-observed short narrow channel in the crystal structure [31, 34] is
insufficient to explain the effects of increasing DNA length on reaction rates.
Effect of topoisomerase I peptide size on TDP1 cleavage
To generate a series of TDP1 substrates with increasing polypeptide lengths, we took
advantage of the observation that combining certain pairs of topoisomerase I fragments
reconstitutes near wild type enzyme activity [37, 38]. The schematic shown in Figure 4
illustrates how these reconstituted forms of the enzyme, when exposed to a suicide substrate,
will produce topoisomerase I-DNA covalent complexes with the fragment containing the
active site Y723 attached to a 12-mer DNA. The pairs of fragments used for the
reconstitution experiments in this study are as follows: topo6.3/topo56, topo12/topo58,
topo39/topo31 (Figure 5A). After suicide cleavage, subsequent purification of the DNA-
protein complexes by SDS-PAGE followed by renaturation of the proteins (Material and
Methods) generated the TDP1 substrates 12-topo6.3, 12-topo12, and 12-topo39. As a control
substrate, we used the same suicide oligonucleotide to generate 12-topo70 (Figure 5A),
which we have shown previously is a very poor substrate for TDP1 [24].
Each of the protein-DNA complexes was incubated with TDP1 for 20 min. Prior to the
analysis of the TDP1 cleavage reactions by electrophoresis in a sequencing gel, the reactions
were treated with trypsin to convert all of the remaining substrate to 12-pep which was well
separated in the gel from the 3′ phosphorylated 12-mer that is the product of the TDP1
reaction (Figs. 4 and 5B). Since a small amount of suicide cleavage occurred two
nucleotides upstream of the major cleavage site (small arrow, Figure 4), some of the
substrate contained a 10-mer oligonucleotide instead of the 12-mer, resulting in a 10-P
product and a residual substrate band called 10-pep.
It has been shown previously that denaturation of the protein moiety of a protein-DNA
complex renders the linkage between the protein and the DNA susceptible to TDP1 cleavage
regardless of the size of the protein [14, 24]. Thus an important control for the cleavage
experiments that follow below was to establish what fraction of the protein had properly
folded during the renaturation step of the substrate preparation. To determine the efficiency
of renaturation, we measured the ability of the protein in the purified complexes (12-
topo6.3, 12-topo12, 12-topo39 and 12-topo70) to support the topoisomerase I religation
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reaction. This measurement required the addition of the complementing protein fragment, a
longer complementary oligonucleotide, and an acceptor oligonucleotide for the religation
reaction as shown in Figure 4 (thick lines depict the added components). The fraction of the
labeled oligonucleotide converted to the 25-mer religation product provides a measure of the
amount of properly folded protein in each substrate preparation. Only for those substrates
where the percentage of the protein-DNA complex that is cleaved by TDP1 exceeds the
percentage that remains unreligated and therefore not properly folded, can we infer that the
complex containing the native protein is a functional substrate for the enzyme.
The results of a representative experiment are shown in Figure 5(B). It can be seen that 12-
topo12 and 12-topo6.3 are essentially completely cleaved to produce predominantly the 12-
P product with a small amount of 10-P (lanes 6-9). Quantifying the radioactive bands
revealed that the religation efficiency for 12-topo12 and 12-topo6.3 was only 23% and 21%
respectively, but the corresponding percentages remaining unreligated (77% and 79%,
respectively) was clearly less than the percent cleavage (Table 1). Thus both the 53 amino
acid topo6.3 and the 108 amino acid topo12 are cleaved from the DNA in the native state.
On the other hand, the percentage of 12-topo70 and 12-topo39 cleaved by TDP1 was less
than the percentage remaining unreligated (Figure 5B, Table 1) and therefore all of the
cleavage could be accounted for by the fraction of the topoisomerase I fragment remaining
unfolded and unable to support the religation reaction. The small amount of cleavage
observed here for the 12-topo70 substrate was comparable to that observed previously for a
topo70-derived substrate which had never been subjected to a cycle of denaturation and
renaturation [24], suggesting that the protein had effectively renatured under the conditions
used here. It is unknown why the topo12 and topo6.3 proteins did not renature as well as the
topo70 protein (Table 1). Taken together, these results indicate that the topoisomerase I-
derived portion of a TDP1 substrate can be as long as 108 amino acids (topo12), but not as
long as 333 amino acids (topo39) for efficient cleavage by TDP1.
Dependence of TDP1 cleavage on in vivo proteolysis
The mutation in the TDP1 gene that causes the neurological disease SCAN1 changes H493
to an arginine and results in the accumulation of the TDP1-DNA covalent reaction
intermediate [17]. We have previously demonstrated that this covalent intermediate can be
detected after exposure of SCAN1 mutant cells to CPT by a modified in vivo complex of
enzyme (ICE) assay in which protein-DNA covalent complexes are separated from the bulk
of the protein in cell extracts by sedimentation through a CsCl cushion with a density of 1.5
g/cc [18, 43]. We reasoned that if the activity of the proteasome were to be required prior to
TDP1 cleavage as suggested by the in vitro data [24, 35], then the presence of a proteasome
inhibitor before the CPT treatment should block the formation of the H493R TDP1-DNA
covalent complexes in SCAN1 cells. Consistent with our earlier results [18], both
topoisomerase I and TDP1 were detected by an immunoblot assay in the ICE pellet after
CPT treatment of SCAN1 cells, but not in the control cells without the drug (Figure 6A,
lanes 1 and 2). The presence of proteasome inhibitors MG132 or lactacystin in the cultures
prior to the addition of CPT prevented the appearance of the H493R TDP1 in the protein-
DNA complex fraction of the ICE assay (Figure 6A, lanes 4 and 6). The control
immunoblots of samples from the whole cell extracts used in the ICE analyses (Figure 6B)
showed that all of the extracts contained equal amounts of TDP1. These results demonstrate
that proteolysis of the topoisomerase I moiety of the enzyme-DNA covalent complex is a
prerequisite for TDP1 cleavage.
Discussion
As a repair enzyme, TDP1 exhibits considerable versatility in removing a diverse spectrum
of adducts from the 3′ end of DNA. In addition to a tyrosine residue, the enzyme can
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hydrolyze 3′ phosphodiester linkages involving short peptides, a nucleoside, an abasic
residue, an artificial biotin adduct, and a glycolate moiety [10, 22-24]. The feature common
to all of these substrates is DNA, but there is a discrepancy between the biochemical and
structural observations concerning whether the DNA is single or double stranded. In a
crystal structure containing an oligonucleotide six bases in length, only the three nucleotides
closest to the scissile phosphate are visible and they occupy a narrow groove extending
away from the active site [31, 34]. This groove extends beyond the electron density of the
DNA for approximately another three nucleotides, leading to the conjecture that the DNA
portion of the substrate contacts the surface of the enzyme within this groove for a total of
about six nucleotides. Importantly, modeling studies indicate that this groove is too narrow
to accommodate duplex DNA [31, 34].
On the other hand, biochemical studies indicate that a substrate containing duplex DNA is as
effectively cleaved as those with single-stranded DNA [13, 14, 19]. To address whether
binding of a duplex substrate caused melting of the DNA near the site of cleavage, Raymond
et al. [19] asked whether mismatches in the DNA would improve cleavage of a duplex
substrate by favoring the melting process. They found instead that substrates with
mismatches were poorer rather than better substrates. To reconcile the biochemical results
with the crystal structure findings, they suggested an alternate model in which the first three
nucleotides of a duplex DNA follow the path described for single-stranded DNA, but instead
of continuing in the narrow groove, the DNA was proposed to bend upwards and track along
one of the faces of the protein adjoining the groove [19]. While this model nicely accounts
for the ability of the enzyme to cleave both single- and double-stranded DNAs with near
equal efficiency, it fails to account for the DNA length dependence observed in the present
study.
Our results suggest that the affinity of TDP1 for the DNA portion of the substrate increases
as the length of the DNA is increased from 6 to 19 nucleotides and modestly increases
further on extending the length to 28 nucleotides. Similarly, it was found by fluorescence
anisotropy analysis that the affinity for a substrate with a 50-mer DNA was significantly
greater that a very similar substrate containing a 10-mer DNA [20]. Although this effect
could, in principle, be attributable to sequence rather than length, we regard this as unlikely
since the Km values determined by other investigators were nearly identical despite
completely different DNA sequences used for the substrates [35, 44, 45].
To explain these observations on length dependence, we propose that the DNA, whether
single- or double-stranded, follows the trajectory out of the active site proposed by
Raymond et al. [19], and that intimate contact of the DNA with the surface of the enzyme is
extended by a wrapping of the DNA around the protein. This suggestion is consistent with
the observation that the protein surface predicted to contact the DNA is largely positively
charged [31, 32]. Our data in combination with those of Raymond et al. [19] indicate that the
trajectory of the DNA on the surface of TDP1 points away from the narrow groove
originally suspected to be occupied by the DNA [32] and likely remains in contact with the
surface of the protein for up to two turns of the DNA helix. If this suggestion is correct, it is
likely that TDP1 can initially bind to DNA at internal sites before the 3′ end is inserted in
the active center of the enzyme as recently suggested by Dexheimer et al. [20]. Definitive
proof for this hypothesis must await a co-crystal structure of TDP1 containing a bound DNA
on the order of 20 nucleotides in length.
Previous results have shown that covalent complexes between DNA and the native form of a
protein are refractory to cleavage by TDP1 [14, 24, 35]. The size of the protein alone is not
the issue, since denaturation by heat or detergent renders the linkage susceptible to TDP1
[14, 24]. Interestingly, the covalent intermediate in the TDP1 reaction is susceptible to
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cleavage by TDP1 itself without denaturation of the protein [24]. The structural basis for this
curious exception is unknown, but it seems unlikely to be due simply to the fact that TDP1
is linked to the DNA through a phosphoamide bound involving histidine whereas the bond
to a type IB topoisomerase is a tyrosine phosphodiester linkage. In both cases, the bond that
must be cleaved by TDP1 is buried within the protein [32, 47] and the lack of accessibility is
probably sufficient to explain why the native topoisomerase I linkage is not cleaved. One
explanation for the susceptibility of the TDP1-DNA bond is that the interaction of this
substrate with TDP1 sufficiently unfolds the protein to expose the scissile bond in the
complex to the active site of the TDP1.
Our finding that a covalent complex involving a folded form of the C-terminal-most 53
amino acids of human topoisomerase I is susceptible to TDP1cleavage is consistent with
earlier structural models in which a C-terminal topoisomerase I fragment 46 amino acids in
length was successfully docked into the protein binding pocket of TDP1 [32]. Here we show
that the fully folded 108 amino acid topoisomerase I peptide can generate a complex that is
still cleaved by TDP1. However, increasing the length of the peptide to 333 amino acids
produces a substrate that, like the full length native topoisomerase I protein, is resistant to
TDP1. These results show that, prior to cleavage by TDP1, the protein moiety of the
topoisomerase I-DNA covalent complexes must either be unfolded or degraded by
proteolysis to a length somewhere in the range of 108 to 333 amino acids.
A variety of studies indicate that the proteasome is involved in the degradation of
topoisomerase I after treatment of cells with CPT [48-52], but these studies have not directly
addressed whether this breakdown was required for the action of TDP1. However, a
previous study demonstrated that MG132 blocks the conversion of CPT-induced
topoisomerase I complexes in SCAN1 cells to single-strand breaks that can be detected by
the alkaline comet assay [21]. Presumably the single-strand breaks that form in the absence
of the proteasome inhibitor still retain a topoisomerase-related peptide that is not further
repaired in the absence of TDP1 in SCAN1 cells, but is rapidly repaired in normal cells.
Here we show by a more direct assay that in the presence of CPT, proteasome inhibitors
block cleavage by the H493R mutant form of TDP1 and thereby prevent the trapping of the
mutant enzyme on the DNA. Therefore the combined results of two independent studies
using different methods strongly support the view that substrate processing by proteolysis is
a prerequisite to cleavage by TDP1.
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Figure 1. TDP1 substrate competition experiments
(A) Pairs of 5′ end-labeled TDP1 substrates (19-pep/12-pep, 12-pep/6-pep, and 19-pep/6-
pep) were incubated for the indicated times with TDP1 and the products analyzed by
electrophoresis in a sequencing gel. The mobilities of the substrates and products (19-P, 12-
P, and 6-P) are indicated along the left side of the panel. (B) and (C) For each experiment,
the percentage of the substrate remaining at each time point was quantified by
PhosphorImager analysis using the ImageQuant software and the results depicted
graphically. Results are means ± S.D. for three independent experiments. Panel B: closed
triangles, 19-pep; closed squares, 12-pep. Panel C: open squares, 12-pep; closed squares, 6-
pep.
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Figure 2. TDP1 competition experiment using the 28-pep/19-pep pair of substrates
The results for the 28-pep/19-pep competing pair of substrates are shown graphically as
described for Figure 1. Results are means ± S.D. for six independent experiments. Closed
diamonds, 28-pep; closed triangles, 19-pep.
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Figure 3. Gel shift experiments
The indicated 5′ end-labeled TDP1 substrates were incubated with two-fold increasing
concentrations of TDP1 (from 23 nM up to 1.46 μM) and subjected to native gel
electrophoresis. The gels were dried and analyzed using the PhosphorImager (A-D). The
first lane in each panel shows the mobility of the substrate in the absence of added TDP1.
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Figure 4. Schematic showing the experimental protocol for varying the size of the protein
portion of the TDP1 substrate
A reconstituted form of human topoisomerase I was used to cleave a 5′ end-labeled suicide
substrate containing a 14-mer scissile strand and a 25-mer non-scissile strand. The major
and minor suicide cleavage sites in the substrate are indicated by the large and small arrows,
respectively. After cleavage, the C-terminal fragment containing the active site tyrosine
(Y723) linked to DNA was gel-purified and subjected to renaturation conditions. This
procedure was used to generate the following four TDP1 substrates: 12-topo6.3, 12-topo12,
12-topo39, 12-topo70. The product from treating these substrates with TDP1 was 5′ end-
labeled 12-P (minor cleavage site produced 10-P, not shown). Prior to the sequencing gel
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analysis of the products, the reactions were treated with trypsin to convert all of the
substrates into 12-pep (and a small amount of 10-pep, not shown). The extent refolding of
the proteins was evaluated by the capacity of the renatured complexes to carry out the
religation reaction to REL13 to produce a 25-mer religation product. The components that
were added to the substrates for the religation reaction are indicated in the figure by the
thick lines (lower right).
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Figure 5. Dependence of TDP1 cleavage on the size of the protein portion of the substrate
(A) The domain structure of human topoisomerase I is drawn to scale and shown across the
top of the panel. The start and end points (indicated by amino acid position) of the TDP1
substrates and the reconstituting fragments are shown schematically below with the number
of amino acids in the protein fragments indicated in parentheses. The line with the asterisk
on the substrates denotes the 5′ end-labeled 12-mer that is covalently attached to the active
site tyrosine. (B) The TDP1 substrates were incubated without (−) and with (+) TDP1
followed by treatment with trypsin and analysis by sequencing gel electrophoresis (lanes
1-9). The mobilities of the substrates and products are given along the left side of the panel.
The products of the religation reaction for each of the substrates are shown in lanes 10-13.
The 14-mer and 25-mer marker DNAs were included in lanes 1 and 14, respectively.
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Figure 6. Effect of proteasome inhibitors on cleavage by H493R mutant form of TDP1
(A) SCAN1 cells were incubated with CPT with and without prior treatment with either
MG132 or lactacystin and the high molecular DNA was isolated by the ICE assay (lanes 2,
4, 6). Control incubations without CPT were included (lanes 1, 3, 5). The DNA pellets from
the ICE assays were treated with Micrococcal nuclease and subjected to immunoblot
analyses probing for topoisomerase I (topo) or TDP1. (B) Samples of the whole cell extracts
used in the ICE assay were similarly subjected to an immunoblot analysis. In addition to
probing for topoisomerase I and TDP1, the blots were probed for β -actin as a loading
control.
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TABLE 11
Substrate Percent cleaved by TDP1 Percent unreligated
12-topo70 28 ± 3 36 ± 5
12-topo39 25 ± 2 52 ± 3
12-topo12 96 ± 2 77 ± 2
12-topo6.3 95 ± 2 79 ± 2
1
Values are the average of two independent analyses of the samples shown in Figure 5B with the indicated errors reflecting the observed range.
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